Company’s Product and Product Candidates

Rituxan® (Rituximab), our first product approved for marketing in the United States, and our primary products still under development, address immune system disorders, such as lymphomas and autoimmune and inflammatory diseases, such as psoriasis, rheumatoid arthritis and allergic asthma. The products are either commercialized or in preclinical and clinical development by IDEC and its partners include the following:

Principal Development Programs

Cancer
Product Candidate Indication Status Partnerships
Rituxan®
(MabThera,
Rituximab,
IDEC-C2B8)
Certain B-cell NHL US: Approved
EU: Approved
Japan: Phase III
Genentech (co-promotion)
Roche
Zenyaku (Japan)
ZEVALIN TM
(IDEC-Y2B8;
anti-CD20)
Certain B-cell NHL Phase III completed Schering AG (ex-US)
Autoimmune Disease and Inflammatory Disease
Product Candidate Indication Status Partnerships
IDEC-131
(Humanized
anti-CD40L)
Systemic Lupus
Erythyematous (SLE)
Phase II completed Eisai (Europe and Asia)
IDEC-151
(Primatized
anti-CD4)
Rheumatoid Arthritis Phase II None
IDEC-152
(Primatized
anti-CD23)
Asthma Phase I Seikagaku (Europe
and Asia)
IDEC-114
(Primatized®
anti-CD80)
Psoriasis Phase I/II Mitsubishi (Asia)

Contract Manufacturing Services
The Company can support a wide range of support services to meet the manufacturing needs of other companies. These include: quality assurance and control, engineering, regulatory affairs, legal services, validation services, process development and fill/finish.